BehemothLabz today announced the publication of a research-use overview examining Cardarine, also known as GW-501516, and its role as an investigational reference compound in PPARd pathway research.

The overview is intended for qualified laboratories and researchers evaluating compounds used in controlled investigational settings. It discusses Cardarine's proposed mechanism of action, preclinical research applications, regulatory status, and supplier evaluation considerations for 2026.

BehemothLabz said interest in PPAR-pathway research continues to grow as laboratories study metabolic signaling, mitochondrial-associated pathways, substrate utilization, and lipid metabolism in preclinical and in vitro research models. According to the company, GW-501516 remains a frequently searched and requested investigational compound among researchers studying PPARd activation.

Cardarine is an investigational small-molecule compound classified as a PPARd, or Peroxisome Proliferator-Activated Receptor Delta, agonist. The overview notes that Cardarine is sometimes incorrectly grouped with SARMs, or Selective Androgen Receptor Modulators, although it does not act on androgen receptors. Instead, it belongs to the PPAR agonist class, a group of nuclear receptor-targeting compounds involved in research related to lipid metabolism and energy homeostasis.

The compound is also known by several synonyms, including GW501516, GW-501,516, GW1516, GSK-516, and Endurobol. Its molecular formula is C21H18F3NO3S2, with a molar mass of approximately 453.49 g/mol and CAS Number 317318-70-0.

In preclinical evaluations, Cardarine has been observed as a high-affinity, high-potency agonist at the PPARd receptor. The overview explains that activation of PPARd has been studied in connection with fatty acid b-oxidation, intracellular activity, and metabolic modulation in laboratory research models.

Preclinical studies in animal models have examined GW-501516 for its role in cellular energy utilization, including research related to fatty acid substrates, glucose-associated pathways, and mitochondrial lipid-processing enzymes. Additional controlled cellular studies have explored interactions with inflammatory and metabolic signaling pathways, including IL-6-mediated signaling and STAT3 activation. BehemothLabz emphasized that these findings remain limited to experimental and preclinical research contexts.

The publication also outlines several research domains in which Cardarine has been studied, including PPARd activation, receptor binding, downstream transcriptional regulation, substrate utilization pathway analysis, oxidative pathway signaling, mitochondrial-associated energy processes, and lipid-profile research in preclinical models.

BehemothLabz includes a regulatory-status section noting that Cardarine's development as a pharmaceutical candidate was discontinued in 2007 following preclinical toxicology findings in long-term animal studies. The compound has not been approved by the U.S. Food and Drug Administration for clinical or human use. The overview also notes that the World Anti-Doping Agency has designated GW-501516 as a prohibited substance.

The company said any research involving Cardarine should occur only under appropriate institutional, ethical, and laboratory oversight, using material intended strictly for controlled investigational and laboratory purposes.

The overview also provides guidance for evaluating research-grade Cardarine suppliers in 2026. BehemothLabz said laboratories should consider batch-specific Certificates of Analysis, third-party purity and identity testing, traceability by batch number, research-use-only labeling, and documentation that avoids therapeutic, dosing, or consumer-use claims.

BehemothLabz states that it supplies Cardarine, or GW-501516, exclusively for laboratory and investigational research. The company also states that it provides third-party testing documentation for batches and offers research formats intended for controlled laboratory applications. According to BehemothLabz, product and testing information should be reviewed by qualified researchers before any laboratory purchase or use.

As laboratories continue to investigate PPAR-pathway modulation, mitochondrial signaling, lipid metabolism, structural characterization, pharmacokinetic behavior, and solid-form properties, BehemothLabz said Cardarine is expected to remain a reference compound in preclinical and analytical research literature.

More information is available at https://behemothlabz.com/.

Research-Use and Regulatory Notice

Cardarine, also known as GW-501516, is not approved by the U.S. Food and Drug Administration for human or veterinary use. It is not a drug, dietary supplement, food, cosmetic, performance-enhancement product, or consumer health product. It is not intended for ingestion, injection, topical use, diagnosis, treatment, cure, prevention, athletic performance enhancement, bodybuilding use, weight-management use, or use by consumers. Cardarine has been designated as a prohibited substance by the World Anti-Doping Agency. Any research involving Cardarine should be conducted only by qualified researchers in controlled laboratory settings under appropriate institutional, ethical, regulatory, and safety oversight.

About BehemothLabz

Founded in 2014, BehemothLabz supplies third-party-tested research compounds, including SARMs, peptides, and PPAR-pathway agonists, to qualified laboratories and researchers. All products are intended strictly for laboratory and investigational research purposes and are not for human or veterinary use. More information is available at https://behemothlabz.com/.

Media Contact

BehemothLabz

Website: https://behemothlabz.com/

Email: support@behemothlabz.com